RXST - NASDAQ
RxSight, Inc.
$4.79
-2.3%RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
At a Glance
Live SnapshotRxSight, Inc. Management Team
Mr. Matt Haller Ph.D.
Chief Technology Officer
Mr. Eric J. Weinberg
Co-President & Chief Commercial Officer
Compensation
$877,380
Ms. Shelley B. Thunen
Co-President & Chief Financial Officer
Compensation
$877,380
Dr. Ilya Goldshleger Ph.D.
Co-President & Chief Operating Officer
Compensation
$899,880
Dr. Ronald M. Kurtz M.D.
Co-President, Chief Executive Officer & Director
Compensation
$1,444,570
Mr. Scott Gaines
Executive Vice President of Manufacturing & Commercial Operations
Mr. Roy Freeman
Senior Vice President of Marketing & Professional Relations
Mr. Steve Everly
Senior Vice President of Sales of North America
Ms. Caroline Vaughn
Vice President of Human Resources
Mr. Oliver Moravcevic
Vice President of Investor Relations
RxSight, Inc. Insider Positioning
During the last 12 months, insiders have purchased $34K worth of RXST shares, with no selling activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
8.3K
34.48K
0
0.00
+34K
+$34K
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
Goldshleger Ilya
Officer: See Remarks
$34K
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $34K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Insider Participation
1 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Unanimous insider buying: Zero selling combined with active buying is rare and typically very bullish. Insiders appear to see significant upside with limited downside risk.
SEC Filings
RXST - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | April 27, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 21, 2025 | April 21, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 25, 2024 | April 25, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 20, 2023 | June 01, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 21, 2022 | June 02, 2022 | 2022 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.